Information Provided By: 
Fly News Breaks for November 27, 2018
HALO
Nov 27, 2018 | 09:00 EDT
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
News For HALO From the Last 2 Days
There are no results for your query HALO
